Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA

Lancet (London, England)2 Jul 2015Cited by 426 (Europe PMC)

PMID26144908PMCIDPMC4620731DOI10.1016/s0140-6736(15)61120-5PepBankPUB-26144908

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study18

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone18

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, the teriparatide-to-denosumab regimen increased spine BMD by 18·3% over 48 months.
In plain wordsIn women with osteoporosis, spine density increased during the teriparatide-to-denosumab regimen.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine BMD after teriparatide to denosumab
Study
n = 27
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine BMD change
18.3%
teriparatide to denosumab
Source sentences
Summary
After 48 months, the primary outcome of mean spine bone mineral density increased by 18·3% (95% CI 14·9-21·8) in 27 women in the teriparatide to denosumab group
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490801
02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, the denosumab-to-teriparatide regimen increased spine BMD by 14·0% over 48 months.
In plain wordsIn women with osteoporosis, spine density increased during the denosumab-to-teriparatide regimen.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine BMD after denosumab to teriparatide
Study
n = 27
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine BMD change
14%
denosumab to teriparatide
Source sentences
Summary
14·0% (10·9-17·2) in 27 women the denosumab to teriparatide group
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490802
03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased spine BMD by 16·0% over 48 months.
In plain wordsIn women with osteoporosis, spine density increased during combined teriparatide and denosumab followed by denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine BMD after combination to denosumab
Study
n = 23
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Spine BMD change
16%
combination to denosumab
Source sentences
Summary
16·0% (14·0-18·0) in 23 women in the combination to denosumab group
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490803
04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, spine BMD gains did not differ significantly between teriparatide-to-denosumab and denosumab-to-teriparatide regimens.
In plain wordsIn women with osteoporosis, spine density gains did not differ significantly between teriparatide-to-denosumab and denosumab-to-teriparatide regimens.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSpine BMD: teriparatide to denosumab versus reverse sequence
Study
n: not reported in source
Comparator
Denosumab to teriparatide
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
although this increase did not differ significantly between groups (for between-group comparisons, p=0·13 for the teriparatide to denosumab group vs the denosumab to teriparatide group,
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490804
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, spine BMD gains did not differ significantly between teriparatide-to-denosumab and combination-to-denosumab regimens.
In plain wordsIn women with osteoporosis, spine density gains did not differ significantly between teriparatide-to-denosumab and combination-to-denosumab regimens.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSpine BMD: teriparatide to denosumab versus combination sequence
Study
n: not reported in source
Comparator
Combination to denosumab
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
p=0·30 for the teriparatide to denosumab group vs the combination to denosumab group,
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490805
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, spine BMD gains did not differ significantly between denosumab-to-teriparatide and combination-to-denosumab regimens.
In plain wordsIn women with osteoporosis, spine density gains did not differ significantly between denosumab-to-teriparatide and combination-to-denosumab regimens.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSpine BMD: denosumab to teriparatide versus combination sequence
Study
n: not reported in source
Comparator
Combination to denosumab
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
p=0·41 for the denosumab to teriparatide group vs the combination to denosumab group).
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490806
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, radius BMD was unchanged over 48 months with teriparatide-to-denosumab.
In plain wordsIn women with osteoporosis, forearm bone density stayed stable during the teriparatide-to-denosumab regimen.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadius BMD after teriparatide to denosumab
Study
n = 27
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Radius BMD change
0%
teriparatide to denosumab
Source sentences
Summary
After 48 months, radius bone mineral density was unchanged in the teriparatide to denosumab group (0·0% [95% CI -1·3 to 1·4]),
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490813
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, radius BMD decreased by -1·8% over 48 months with denosumab-to-teriparatide, with a confidence interval crossing zero.
In plain wordsIn women with osteoporosis, forearm density decreased numerically during denosumab-to-teriparatide, with uncertainty that included no change.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadius BMD after denosumab to teriparatide
Study
n = 27
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Radius BMD change
−1.8%
denosumab to teriparatide
Source sentences
Summary
whereas it decreased by -1·8% (-5·0 to 1·3) in the denosumab to teriparatide group,
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490814
09HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased radius BMD by 2·8% over 48 months.
In plain wordsIn women with osteoporosis, forearm density increased during combined teriparatide and denosumab followed by denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius BMD after combination to denosumab
Study
n = 23
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Radius BMD change
2.8%
combination to denosumab
Source sentences
Summary
and increased by 2·8% (1·2-4·4) in the combination to denosumab group (
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490815
10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, total hip BMD increased more with teriparatide-to-denosumab than denosumab-to-teriparatide.
In plain wordsIn women with osteoporosis, hip density increased more with teriparatide-to-denosumab than denosumab-to-teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD: teriparatide to denosumab versus reverse sequence
Study
n: not reported in source
Comparator
Denosumab to teriparatide
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
6.6%
teriparatide to denosumab
Total hip BMD change
2.8%
denosumab to teriparatide
Source sentences
Summary
For the bone mineral density secondary outcomes, total hip bone mineral density increased more in the teriparatide to denosumab group (6·6% [95% CI 5·3-7·9]) than in the denosumab to teriparatide group (2·8% [1·3-4·2], p=0·0002)
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490807
11HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased hip BMD more than teriparatide-to-denosumab.
In plain wordsIn women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased hip density more than teriparatide-to-denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD: combination sequence versus teriparatide to denosumab
Study
n: not reported in source
Comparator
Teriparatide to denosumab
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
8.6%
combination to denosumab
Source sentences
Summary
but had the greatest increase in the combination to denosumab group (8·6% [7·1-10·0]; p=0·0446 vs the teriparatide to denosumab group, p<0·0001 vs the denosumab to teriparatide group).
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490808
12HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased hip BMD more than denosumab-to-teriparatide.
In plain wordsIn women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased hip density more than denosumab-to-teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD: combination sequence versus denosumab to teriparatide
Study
n: not reported in source
Comparator
Denosumab to teriparatide
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Total hip BMD change
8.6%
combination to denosumab
Source sentences
Summary
but had the greatest increase in the combination to denosumab group (8·6% [7·1-10·0]; p=0·0446 vs the teriparatide to denosumab group, p<0·0001 vs the denosumab to teriparatide group).
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490809
13HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, femoral neck BMD increased more with teriparatide-to-denosumab than denosumab-to-teriparatide.
In plain wordsIn women with osteoporosis, thighbone neck density increased more with teriparatide-to-denosumab than denosumab-to-teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD: teriparatide to denosumab versus reverse sequence
Study
n: not reported in source
Comparator
Denosumab to teriparatide
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD change
8.3%
teriparatide to denosumab
Femoral neck BMD change
4.9%
denosumab to teriparatide
Source sentences
Summary
Similarly, femoral neck bone mineral density increased more in the teriparatide to denosumab group (8·3% [95% CI 6·1-10·5]) and the combination to denosumab group (9·1% [6·1-12·0]) than in the denosumab to teriparatide group (4·9% [2·2-7·5]; p=0·0447 for teriparatide to denosumab vs denosumab to teriparatide,
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490810
14HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased femoral neck BMD more than denosumab-to-teriparatide.
In plain wordsIn women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased thighbone neck density more than denosumab-to-teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD: combination sequence versus denosumab to teriparatide
Study
n: not reported in source
Comparator
Denosumab to teriparatide
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Femoral neck BMD change
9.1%
combination to denosumab
Femoral neck BMD change
4.9%
denosumab to teriparatide
Source sentences
Summary
and the combination to denosumab group (9·1% [6·1-12·0]) than in the denosumab to teriparatide group (4·9% [2·2-7·5]; p=0·0447 for teriparatide to denosumab vs denosumab to teriparatide, p=0·0336 for combination to denosumab vs denosumab to teriparatide).
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490811
15HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, femoral neck BMD gains did not differ significantly between combination-to-denosumab and teriparatide-to-denosumab regimens.
In plain wordsIn women with osteoporosis, thighbone neck density gains did not differ significantly between combination-to-denosumab and teriparatide-to-denosumab regimens.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD: combination sequence versus teriparatide to denosumab
Study
n: not reported in source
Comparator
Teriparatide to denosumab
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Differences between the combination to denosumab group and the teriparatide to denosumab group did not differ significantly (p=0·67).
2 context sentences(design, population, supporting numbers)
Summary · context
Similarly, femoral neck bone mineral density increased more in the teriparatide to denosumab group
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490812
16HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, the combination-to-denosumab regimen produced greater radius BMD change than teriparatide-to-denosumab.
In plain wordsIn women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased forearm density more than teriparatide-to-denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius BMD: combination sequence versus teriparatide to denosumab
Study
n: not reported in source
Comparator
Teriparatide to denosumab
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Radius BMD change
2.8%
combination to denosumab
Source sentences
Summary
and increased by 2·8% (1·2-4·4) in the combination to denosumab group (p=0·0075 for the teriparatide to denosumab group vs the combination to denosumab group;
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490816
17HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with osteoporosis, the combination-to-denosumab regimen produced greater radius BMD change than denosumab-to-teriparatide.
In plain wordsIn women with osteoporosis, combined teriparatide and denosumab followed by denosumab increased forearm density more than denosumab-to-teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRadius BMD: combination sequence versus denosumab to teriparatide
Study
n: not reported in source
Comparator
Denosumab to teriparatide
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
Radius BMD change
2.8%
combination to denosumab
Source sentences
Summary
and increased by 2·8% (1·2-4·4) in the combination to denosumab group (p=0·0075 for the teriparatide to denosumab group vs the combination to denosumab group; p=0·0099 for the denosumab to teriparatide group vs the combination to denosumab group).
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490817
18HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome
In women with osteoporosis, one participant receiving denosumab-to-teriparatide developed nephrolithiasis, classified as possibly treatment-related.
In plain wordsIn women with osteoporosis, one participant receiving denosumab-to-teriparatide developed kidney stones that were possibly related to treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableNephrolithiasis
Study
n = 27
Outcome group
Adverse events · Kidney and urinary
Measurements
Participants with nephrolithiasis
1 participant
denosumab to teriparatide
Source sentences
Summary
One participant in the denosumab to teriparatide group had nephrolithiasis, classified as being possibly related to treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to both received an additional 24 months of denosumab alone (c…
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2614490818

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 4NCT04467983

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Hospital for Special Surgery, New Yorkn = 701 Feb 2021 to est. 31 Dec 2026

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 13 Oct 2026

CompletedPhase 2Results postedNCT00926380

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis

Massachusetts General Hospitaln = 94Jun 2009 to Dec 2016

Osteoporosis

Trial page ClinicalTrials.govUpdated 29 Jun 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.